Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibrutinib resistance in chronic lymphocytic leukemia.

Literature DB >> 24869597

Ibrutinib resistance in chronic lymphocytic leukemia.

Richard R Furman¹, Shuhua Cheng, Pin Lu, Menu Setty, Alexendar R Perez, Alijandro R Perez, Ailin Guo, Joelle Racchumi, Guozhou Xu, Hao Wu, Jiao Ma, Susanne M Steggerda, Morton Coleman, Christina Leslie, Y Lynn Wang.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2014 PMID： 24869597 PMCID： PMC4512173 DOI： 10.1056/NEJMc1402716

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

6 in total

1. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors: Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal: Blood Date: 2011-03-21 Impact factor: 22.113

2. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Authors: Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd
Journal: N Engl J Med Date: 2014-05-28 Impact factor: 91.245

3. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors: Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal: Proc Natl Acad Sci U S A Date: 2010-07-06 Impact factor: 11.205

4. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors: Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal: J Clin Oncol Date: 2012-10-08 Impact factor: 44.544

5. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Authors: S Cheng; J Ma; A Guo; P Lu; J P Leonard; M Coleman; M Liu; J J Buggy; R R Furman; Y L Wang
Journal: Leukemia Date: 2013-11-25 Impact factor: 11.528

6. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

6 in total

111 in total

Review 1. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors: Adrian Wiestner
Journal: Haematologica Date: 2015-12 Impact factor: 9.941

2. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Authors: Zachary A Hing; Rose Mantel; Kyle A Beckwith; Daphne Guinn; Erich Williams; Lisa L Smith; Katie Williams; Amy J Johnson; Amy M Lehman; John C Byrd; Jennifer A Woyach; Rosa Lapalombella
Journal: Blood Date: 2015-04-02 Impact factor: 22.113

Review 3. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors: Kelly Valla; Christopher R Flowers; Jean L Koff
Journal: Expert Opin Investig Drugs Date: 2018-06-07 Impact factor: 6.206

Review 4. A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors: Mazie Tsang; Sameer A Parikh
Journal: Curr Hematol Malig Rep Date: 2017-02 Impact factor: 3.952

5. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors: Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal: Blood Date: 2017-01-03 Impact factor: 22.113

6. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk^C481S mutation in B-cell malignancies.

Authors: Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal: Br J Pharmacol Date: 2019-12-09 Impact factor: 8.739